Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Other Working Capital Changes (2016 - 2025)

Bio-Techne has reported Other Working Capital Changes over the past 17 years, most recently at -$338000.0 for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$338000.0 for Q4 2025, up 88.15% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 242.05% YoY), and the annual figure for FY2025 was $675000.0, down 78.54%.
  • Other Working Capital Changes for Q4 2025 was -$338000.0 at Bio-Techne, down from $1.0 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for TECH hit a ceiling of $3.2 million in Q1 2022 and a floor of -$2.9 million in Q2 2022.
  • Median Other Working Capital Changes over the past 5 years was $146000.0 (2021), compared with a mean of $158150.0.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 2119.44% in 2022 and later surged 970.29% in 2024.
  • Bio-Techne's Other Working Capital Changes stood at -$114000.0 in 2021, then crashed by 562.28% to -$755000.0 in 2022, then surged by 176.42% to $577000.0 in 2023, then tumbled by 594.45% to -$2.9 million in 2024, then soared by 88.15% to -$338000.0 in 2025.
  • The last three reported values for Other Working Capital Changes were -$338000.0 (Q4 2025), $1.0 million (Q3 2025), and $148000.0 (Q2 2025) per Business Quant data.